Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231424 | 0.96 | MEN1 (0.43) | GPR119ALDH1A1LMNAMAPTKCNH2 | |
| SCHEMBL4613647 | 0.76 | SMARCA2 (0.50) | GPR119ALDH1A1LMNAMAPTKCNH2 | |
| SCHEMBL2165432 | 0.76 | KDM4E (0.54) | GPR119ALDH1A1LMNAMAPTKCNH2 | |
| SCHEMBL5336615 | 0.76 | ALDH1A1 (0.57) | GPR119ALDH1A1LMNAMAPTKCNH2 | |
| SCHEMBL5683482 | 0.75 | THRB (0.48) | ALDH1A1LMNAMAPTKCNH2MEN1 | |
| SCHEMBL5235485 | 0.75 | ALDH1A1 (0.49) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL652792 | 0.74 | GRM5 (0.53) | GPR119ALDH1A1LMNAMAPTSMARCA2 | |
| SCHEMBL31651879 | 0.73 | EGLN2 (0.44) | GPR119ALDH1A1LMNAMAPTKCNH2 | |
| SCHEMBL18342019 | 0.73 | KCNH2 (0.45) | GPR119ALDH1A1LMNAMAPTKCNH2 | |
| SCHEMBL5231466 | 0.73 | CDK8 (0.47) | ALDH1A1LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | GPR119 558/4885ALDH1A1 1073/4885LMNA 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.